Verona Pharma Stock Price, News & Analysis

Verona Pharma plc (Nasdaq: VRNA) announced successful Phase 3 ENHANCE-2 trial results for nebulized ensifentrine, demonstrating significant improvements in lung function and a 42% reduction in moderate to severe COPD exacerbations over 24 weeks. The trial met primary and secondary endpoints, showing notable safety and tolerability similar to placebo. Ensifentrine is a first-in-class dual inhibitor targeting COPD treatment. The company plans to submit a New Drug Application to the FDA in early 2023, contingent on ongoing trial results.

Verona Pharma announces the reporting of top-line Phase 3 data from its ENHANCE-2 trial on August 9, 2022. This trial evaluates the efficacy of nebulized ensifentrine for the treatment of COPD. The company will also disclose its financial results for Q2 2022 during an investment community webcast at 8:30 a.m. EDT. Notably, the ENHANCE program includes two studies focused on lung function improvements over 24 weeks, with primary endpoints measuring FEV₁. Verona Pharma seeks to address significant unmet needs in respiratory diseases.

Verona Pharma (Nasdaq: VRNA) will announce its second-quarter financial results for the period ending June 30, 2022, on August 15, 2022. A conference call for investors is scheduled for 9:00 a.m. EDT to discuss these results and provide updates on the company’s operations. Verona Pharma is a clinical-stage biopharmaceutical company dedicated to developing therapies for respiratory diseases, specifically through its product candidate, ensifentrine, which is currently in Phase 3 trials for COPD maintenance treatment.

Verona Pharma has completed patient enrollment for its Phase 3 ENHANCE clinical trials, with over 800 subjects in the ENHANCE-1 trial and more than 1,600 across both ENHANCE-1 and ENHANCE-2 trials for ensifentrine, targeting chronic obstructive pulmonary disease (COPD).

Top-line data is anticipated in Q3 2022 and late 2022. The study aims to demonstrate the efficacy of ensifentrine in improving lung function and quality of life for COPD patients, potentially marking a significant advancement in treatment options.

Verona Pharma plc (Nasdaq: VRNA) will host an in-person KOL event on June 16, 2022, at 8:00 AM ET in New York. The event will feature discussions on COPD treatment, focusing on unmet needs and the potential of ensifentrine. Key opinion leaders, Igor Bajaktarevic and Jill Ohar, will share insights. Verona Pharma also plans to release top-line Phase 3 ENHANCE data for COPD in Q3 2022. Ensifentrine aims to be a first-in-class therapy, combining bronchodilator and anti-inflammatory effects. For details, visit www.veronapharma.com.

Verona Pharma (Nasdaq: VRNA) will have its Senior Vice President of Commercial, Chris Martin, present at the Jefferies Healthcare Conference on June 8, 2022, at 1:30 PM ET. This event will be accessible via a webcast on the company's website. Verona Pharma is a clinical-stage biopharmaceutical company focused on respiratory diseases, currently evaluating nebulized ensifentrine in a Phase 3 clinical program for COPD. Top-line data for this study is anticipated in the third quarter of 2022, with ensifentrine aiming to be a dual-action therapy.

Verona Pharma plc (Nasdaq: VRNA) presented an abstract at the American Thoracic Society International Conference in May 2022, confirming that ensifentrine met all safety objectives in a thorough QT study. The findings, which indicated no significant effects on cardiac conduction, support Verona's upcoming New Drug Application for ensifentrine as a treatment for chronic obstructive pulmonary disease (COPD). The FDA requires such studies for new drug submissions, enhancing the potential for ensifentrine's approval.

Verona Pharma (Nasdaq: VRNA) announced its participation in two key conferences in May 2022. The LifeSci Partners Virtual Immunology & Inflammation Symposium will take place on May 10 at 9:00 AM ET, and the H.C. Wainwright Hybrid Global Investment Conference is scheduled for May 24 at 3:30 PM ET in Miami. Verona Pharma is advancing its Phase 3 clinical program for nebulized ensifentrine, aimed at COPD treatment, with expected top-line data in Q3 2022. Ensifentrine could potentially be a breakthrough therapy combining bronchodilator and anti-inflammatory properties.

Verona Pharma (VRNA) reported its Q1 2022 financial results, highlighting significant progress in its Phase 3 ENHANCE clinical trials for COPD treatment, with 90% enrollment completion. The company anticipates top-line data from ENHANCE-2 in Q3 2022 and plans to submit a New Drug Application to the FDA in H1 2023, pending positive results. Cash and equivalents were $132.8 million as of March 31, 2022, expected to fund operations through 2023. However, net loss increased to $24.8 million from $21.3 million year-over-year.